Recent developments in target identification against hepatitis C virus.
Chronic hepatitis C is a leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. Recent progress in the understanding of the molecular virology of hepatitis C has allowed the identification of novel antiviral targets. Moreover, in vitro and in vivo model systems have been developed that allow the systematic evaluation of new therapeutic strategies. Exciting results from proof-of-concept clinical studies have now been reported for a specific hepatitis C virus serine protease inhibitor. These and other novel antiviral strategies may complement existing therapeutic modalities in the future.
Department of Medicine II, University of Freiburg, D-79106 Freiburg, Germany. Darius.Moradpour@uni-freiburg.de
Volker
V
Brass
Hubert E
HE
Blum
Darius
D
Moradpour
D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D016174:Hepacivirus / Q000187:drug effects* / Q000201:enzymology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage*
D000998:Antiviral Agents; D015842:Serine Proteinase Inhibitors